Garcia-Guiñon A, Charry PA, Jimenez M, Sarra J, Delgado I, Segura de la Torre L, Santaliestra M, Garcia-Pintos M, Gonzalez Y, Senin A, Motlló C, Abella E, Cabezudo E, Granell M, Sancho E, Herranz MJ, Seres Y, Gironella M, Soler JA, Marti-Tutusaus JM, Ben Azaiz R, Fernandez de Larrea C
Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma.
Manubens A, Paiva B, Gutiérrez NC, Fernandez M, Calasanz MJ, Rosiñol L, Oriol A, Blanchard MJ, Carrillo E, Benavente C, Martínez-López J, Bargay J, Hernández MT, de la Rubia J, González Y, Paricio M, de Arriba F, Ocio EM, Teruel AI, de la Guia AL, Sirvent M, Gironella M, Sampol A, Arguiñano JM, Cabrera C, Alegre A, Granell M, Cabañas V, Núñez-Córdoba JM, Mateos MV, Lahuerta JJ, San Miguel JF, Bladé J, Rodriguez-Otero P
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy.
Moreno DF, Oriol A, de la Rubia J, Hernández MT, Iñigo MB, Palomera L, de Arriba F, González Y, Teruel AI, Pardo JL, López de la Guía A, Sampol A, Ríos-Tamayo R, Sureda A, Gutiérrez NC, Calasanz MJ, Ramos MLM, Mateos MV, San Miguel J, Lahuerta JJ, Bladé J, Rosiñol L
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials.
Cisneros A, Mallo M, Méndez-López A, Villena C, Santafé E, Tijero J, Abel M, Ruiz-Xivillé N, Ibarra G, Abril L, Sureda AM, Escoda L, González-Montes Y, Ortín X, Navarro JT, Oriol A, Solé F, Granada I
Optical Genome Mapping (OGM): Validation and Clinical Utility in the Cytogenetic Diagnosis of Multiple Myeloma.
Moreno, A, Arostegui, IC, Garzo, A, Abril, L, Escoda, L, Casas, A, Ibarra, G, Cañamero, E, Cabezudo, E, Ortin, X, Biosca, C, Viñas, J, Bedoya, T, Giménez, A, Blanco, C, Botafogo, V, Izquierdo, M, Sarrà, J, Montes, YG, Balari, AS, Oriol, A
Impact of Cumulative and Relative Dose Intensity of Bortezomib, Lenalidomide, and Dexamethasone (VRD) on Depth and Duration of Response in Newly Diagnosed Multiple Myeloma (MM)
Medina, AC, Arostegui, IC, Garzo, A, Abril, L, Escoda, L, Cañamero, E, Cabezudo, E, Ortín, X, Biosca, C, Viñas, J, Bedoya, T, Giménez, A, Sarrà, J, Montes, YG, Balarí, AS, Oriol, A
Severe Infections in Newly Diagnosed Multiple Mieloma Patients Treated Frontline with Bortezomib, Lenalidomide and Dexamethasone (VRD) in Four Reference Centers
Mateos, MV, Paiva, B, Cedena, MT, Puig, N, Sureda-Balari, AM, de la Calle, VG, Oriol, A, Ocio, EM, Rosiñol, L, Montes, YG, Bargay, J, García, MEG, Lakhwani, S, Payer, AR, Suarez-Cabrera, A, Blanchard, MJ, Garzón, S, Montero, FC, Cabañas, V, Oteyza, JPD, Gironella, M, Martinez-Lopez, J, Casasús, AIT, Delgado-Beltrán, MP, Prieto, E, Lahuerta, JJ, Bladé, J, San-Miguel, J
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3,-label, multicentre, randomised clinical trial
